Digital Aria Co Ltd Asset Resilience Ratio
Digital Aria Co Ltd asset resilience ratio. Digital Aria Co Ltd (115450) has an Asset Resilience Ratio of 0.92% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Digital Aria Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Digital Aria Co Ltd (2011–2025)
Asset resilience ratio of Digital Aria Co Ltd from 2011 to 2025. This chart shows how Digital Aria Co Ltd's Asset Resilience Ratio has changed over time. Read Digital Aria Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Digital Aria Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Digital Aria Co Ltd balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩2.04 Billion | 0.92% |
| Total Liquid Assets | ₩2.04 Billion | 0.92% |
Asset Resilience Insights
- Limited Liquidity: Digital Aria Co Ltd maintains only 0.92% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Digital Aria Co Ltd Industry Peers by Asset Resilience Ratio
Compare Digital Aria Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Digital Aria Co Ltd Asset Resilience Ratio by Year (2011–2025)
Digital Aria Co Ltd asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Digital Aria Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.23% | ₩25.69 Billion ≈ $17.41 Million |
₩228.66 Billion ≈ $154.96 Million |
-5.95pp |
| 2024-12-31 | 17.19% | ₩37.77 Billion ≈ $25.60 Million |
₩219.79 Billion ≈ $148.95 Million |
+1.07pp |
| 2023-12-31 | 16.11% | ₩32.35 Billion ≈ $21.92 Million |
₩200.79 Billion ≈ $136.08 Million |
-17.97pp |
| 2022-12-31 | 34.08% | ₩63.95 Billion ≈ $43.34 Million |
₩187.64 Billion ≈ $127.16 Million |
-18.90pp |
| 2021-12-31 | 52.98% | ₩100.51 Billion ≈ $68.11 Million |
₩189.71 Billion ≈ $128.56 Million |
+29.37pp |
| 2020-12-31 | 23.61% | ₩28.79 Billion ≈ $19.51 Million |
₩121.94 Billion ≈ $82.64 Million |
-10.90pp |
| 2019-12-31 | 34.51% | ₩48.15 Billion ≈ $32.63 Million |
₩139.52 Billion ≈ $94.55 Million |
+18.85pp |
| 2018-12-31 | 15.66% | ₩16.85 Billion ≈ $11.42 Million |
₩107.66 Billion ≈ $72.96 Million |
+6.24pp |
| 2017-12-31 | 9.42% | ₩5.91 Billion ≈ $4.00 Million |
₩62.71 Billion ≈ $42.50 Million |
+0.55pp |
| 2016-12-31 | 8.87% | ₩4.58 Billion ≈ $3.11 Million |
₩51.65 Billion ≈ $35.00 Million |
+0.93pp |
| 2015-12-31 | 7.94% | ₩4.00 Billion ≈ $2.71 Million |
₩50.35 Billion ≈ $34.12 Million |
-4.02pp |
| 2014-12-31 | 11.96% | ₩7.00 Billion ≈ $4.74 Million |
₩58.52 Billion ≈ $39.66 Million |
+11.37pp |
| 2013-12-31 | 0.59% | ₩216.00 Million ≈ $146.38K |
₩36.69 Billion ≈ $24.86 Million |
+0.01pp |
| 2012-12-31 | 0.58% | ₩313.70 Million ≈ $212.59K |
₩54.32 Billion ≈ $36.81 Million |
-6.93pp |
| 2011-12-31 | 7.51% | ₩4.67 Billion ≈ $3.17 Million |
₩62.23 Billion ≈ $42.17 Million |
-- |
About Digital Aria Co Ltd
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrica… Read more